Advertisement

Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy

Published:November 03, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.09.090
      Inflammation is associated with coronary artery disease (CAD), and statins reduce the inflammatory marker C-reactive protein (CRP). The effects of ezetimibe, alone or in combination with statins, on CRP and low-density lipoprotein (LDL) cholesterol were examined in 2 pooled analyses of randomized, placebo-controlled trials of ezetimibe 10 mg/day in patients with hypercholesterolemia: 6 12-week trials as monotherapy (n = 1,372) and 7 6- to 8-week trials as add-on to baseline statin therapy (n = 3,899). Mean percentage changes from baseline in CRP and LDL cholesterol were examined using analysis of variance in patients with CRP ≤10 mg/L. Effects within subgroups (age, gender, race, body mass index, diabetes mellitus, metabolic syndrome, CAD, baseline CRP or lipids, and statin potency) and correlations between CRP and LDL cholesterol were also examined. Reduction in CRP by ezetimibe monotherapy was numerically greater than with placebo (treatment difference 6%, p = 0.09). Added to statin therapy, ezetimibe was associated with a significant additional reduction in CRP (treatment difference 10%, p <0.001). Treatment effects were generally consistent across subgroups for the 2 analyses. With monotherapy and add-on to statin therapy, LDL cholesterol reduction with ezetimibe was significantly greater than with placebo (treatment differences −19% and −23%, respectively, p <0.001). Spearman's correlation coefficients among baseline values and percentage changes from baseline in CRP and LDL cholesterol ranged from −0.007% to 0.13%. In conclusion, the addition of ezetimibe to statin treatment provides significantly enhanced CRP reductions over and above those achieved with statin monotherapy. Correlations between changes in CRP and changes in LDL cholesterol were weakly positive and significant only when ezetimibe was added to statin treatment. The effects of ezetimibe monotherapy are not well defined. The effects of ezetimibe on CRP were consistent across patient subgroups.
      To read this article in full you will need to make a payment

      References

        • Pearson T.A.
        • Mensah G.A.
        • Alexander R.W.
        • Anderson J.L.
        • Cannon III, R.O.
        • Criqui M.
        • Fadl Y.Y.
        • Fortmann S.P.
        • Hong Y.
        • Myers G.L.
        • et al.
        Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
        Circulation. 2003; 107: 499-511
        • Ballantyne C.M.
        • Nambi V.
        Markers of inflammation and their clinical significance.
        Atheroscler Suppl. 2005; 6: 21-29
        • Black S.
        • Kushner I.
        • Samols D.
        C-reactive protein.
        J Biol Chem. 2004; 279: 48487-48490
        • Zhou Z.
        • Rahme E.
        • Pilote L.
        Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
        Am Heart J. 2006; 151: 273-281
        • Gotto Jr, A.M.
        Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
        Am J Cardiol. 2005; 96: 34F-38F
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Darkes M.J.
        • Poole R.M.
        • Goa K.L.
        Ezetimibe.
        Am J Cardiovasc Drugs. 2003; 3: 67-76
        • Dujovne C.A.
        • Ettinger M.P.
        • McNeer J.F.
        • Lipka L.J.
        • LeBeaut A.P.
        • Suresh R.
        • Yang B.
        • Veltri E.P.
        Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
        Am J Cardiol. 2002; 90: 1092-1097
        • Goldberg A.C.
        • Sapre A.
        • Liu J.
        • Capece R.
        • Mitchel Y.B.
        Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
        Mayo Clin Proc. 2004; 79: 620-629
        • Davidson M.H.
        • McGarry T.
        • Bettis R.
        • Melani L.
        • Lipka L.J.
        • LeBeaut A.P.
        • Suresh R.
        • Sun S.
        • Veltri E.P.
        Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
        J Am Coll Cardiol. 2002; 40: 2125-2134
        • Bays H.E.
        • Ose L.
        • Fraser N.
        • Tribble D.L.
        • Quinto K.
        • Reyes R.
        • Johnson-Levonas A.O.
        • Sapre A.
        • Donahue S.R.
        A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
        Clin Ther. 2004; 26: 1758-1773
        • Melani L.
        • Mills R.
        • Hassman D.
        • Lipetz R.
        • Lipka L.
        • LeBeaut A.
        • Suresh R.
        • Mukhopadhyay P.
        • Veltri E.
        Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
        Eur Heart J. 2003; 24: 717-728
        • Ballantyne C.M.
        • Houri J.
        • Notarbartolo A.
        • Melani L.
        • Lipka L.J.
        • Suresh R.
        • Sun S.
        • LeBeaut A.P.
        • Sager P.T.
        • Veltri E.P.
        Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
        Circulation. 2003; 107: 2409-2415
      1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Pearson T.A.
        • Denke M.A.
        • McBride P.E.
        • Battisti W.P.
        • Brady W.E.
        • Palmisano J.
        A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial.
        Mayo Clin Proc. 2005; 80: 587-595
        • Brohet C.
        • Banai S.
        • Alings A.M.
        • Massaad R.
        • Davies M.J.
        • Allen C.
        LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
        Curr Med Res Opin. 2005; 21: 571-578
        • Farnier M.
        • Volpe M.
        • Massaad R.
        • Davies M.J.
        • Allen C.
        Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
        Int J Cardiol. 2005; 102: 327-332
        • Cruz-Fernandez J.M.
        • Bedarida G.V.
        • Adgey J.
        • Allen C.
        • Johnson-Levonas A.O.
        • Massaad R.
        Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
        Int J Clin Pract. 2005; 59: 619-627
        • Gagne C.
        • Bays H.E.
        • Weiss S.R.
        • Mata P.
        • Quinto K.
        • Melino M.
        • Cho M.
        • Musliner T.A.
        • Gumbiner B.
        Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
        Am J Cardiol. 2002; 90: 1084-1091
        • Pearson T.
        • Ballantyne C.
        • Sisk C.
        • Shah A.
        • Veltri E.
        • Maccubbin D.
        Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
        Am J Cardiol. 2007; 99: 1706-1713
        • Kastelein J.J.
        • Akdim F.
        • Stroes E.S.
        • Zwinderman A.H.
        • Bots M.L.
        • Stalenhoef A.F.
        • Visseren F.L.
        • Sijbrands E.J.
        • Trip M.D.
        • Stein E.A.
        • et al.
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443
        • Ray K.K.
        • Cannon C.P.
        • Cairns R.
        • Morrow D.A.
        • Rifai N.
        • Kirtane A.J.
        • McCabe C.H.
        • Skene A.M.
        • Gibson C.M.
        • Ridker P.M.
        • Braunwald E.
        Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
        J Am Coll Cardiol. 2005; 46: 1417-1424
        • Ridker P.M.
        • Rifai N.
        • Rose L.
        • Buring J.E.
        • Cook N.R.
        Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
        N Engl J Med. 2002; 347: 1557-1565
        • Albert M.A.
        • Danielson E.
        • Rifai N.
        • Ridker P.M.
        Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study.
        JAMA. 2001; 286: 64-70
        • Ansell B.J.
        • Watson K.E.
        • Weiss R.E.
        • Fonarow G.C.
        hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels: a clinical investigation.
        Heart Dis. 2003; 5: 2-7
        • Kinlay S.
        Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
        J Am Coll Cardiol. 2007; 49: 2003-2009
        • Tuzcu E.M.
        • Nicholls S.J.
        Statins targeting inflammation by lowering low-density lipoprotein?.
        J Am Coll Cardiol. 2007; 49: 2010-2012
        • Robinson J.G.
        • Smith B.
        • Maheshwari N.
        • Schrott H.
        Pleiotropic effects of statins: benefit beyond cholesterol reduction?.
        J Am Coll Cardiol. 2005; 46: 1855-1862
        • Davis H.R.
        • Veltri E.P.
        Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
        J Atheroscler Thromb. 2007; 14: 99-108
        • Abate N.
        • Catapano A.L.
        • Ballantyne C.M.
        • Davidson M.H.
        • Polis A.
        • Smugar S.S.
        • Tershakovec A.M.
        Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analysis.
        J Clin Lipidol. 2008; 2: 91-105